Last updated: 2026-09-09 23:57:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Cue Biopharma, Inc. (CUE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $30.53, with a market capitalization of $199.34M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.97 to $45.50. This page covers its latest market performance, valuation, price trends and company information.
$199.34M | |
$29.73 | |
$950.70 | |
$4.97 | |
$30.00 | |
167.74K | |
155.50K | |
-- | |
$45.50 | |
$4.97 | |
-- | |
-- |
Cue Biopharma, Inc. (CUE) is trading at $30.27 in after-hours trading as of 2026-09-09 23:41:00, up 0.90% ($0.27) from the regular-session close of $30.00.
After-hours trading shows how investors are pricing CUE after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Cue Biopharma, Inc. (CUE) moved from $27.88 to $30.53, representing a gain of 9.51% ($2.65).
The stock traded between $25.01 and $32.06 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 126.40 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 63.1%
CUE is currently trading at $30.53, placing it 63.1% of the way from its 52-week low of $4.97 to its 52-week high of $45.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cue Biopharma, Inc. (CUE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.